Boothbay Fund Management’s Palvella Therapeutics PVLA Stock Holding History

Boothbay Fund Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.36M	Buy	+18,962	New	+$1.98M	0.03%	547
2025 Q4	–	Sell	-25,532	Closed	-$1.6M	–	2465
2025 Q3	$1.6M	Buy	+25,532	New	+$1.14M	0.02%	654
2022 Q2	–	Sell	-609	Closed	-$148K	–	2739
2022 Q1	$148K	Sell	609 -204	-25%	-$53.6K	﹤0.01%	1998
2021 Q4	$246K	Hold	813	–	–	0.01%	1362
2021 Q3	$336K	Buy	+813	New	+$283K	0.01%	1270
2020 Q3	–	Sell	-352	Closed	-$87K	–	1260
2020 Q2	$87K	Buy	352 +17	+5%	+$3.98K	0.01%	892
2020 Q1	$61K	Buy	+335	New	+$84.4K	0.01%	773
2019 Q4	–	Sell	-423	Closed	-$115K	–	1024
2019 Q3	$115K	Sell	423 -450	-52%	-$174K	0.01%	694
2019 Q2	$328K	Buy	+873	New	+$260K	0.03%	515

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boothbay Fund Management's PVLA Position: Q1 2026 in Review

Boothbay Fund Management opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 18,962 shares worth $2.36M. The stake represents 0.03% of the portfolio and ranks #547 among its holdings. This is a return to the name: Boothbay Fund Management previously reported a position in PVLA as recently as Q3 2025.

Boothbay Fund Management first reported a position in PVLA in Q2 2019 and has held it in 9 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

Boothbay Fund Management held 18,962 shares of Palvella Therapeutics worth $2.36M as of Q1 2026.
Palvella Therapeutics was a new Boothbay Fund Management position in Q1 2026.
Palvella Therapeutics made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #547 holding.
Boothbay Fund Management first reported a position in Palvella Therapeutics in Q2 2019 and has held it in 9 quarters since.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.